{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:38:45Z","timestamp":1792291125044,"version":"4.4.0"},"reference-count":32,"publisher":"Japanese Circulation Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2018]]},"DOI":"10.1253\/circj.cj-17-0179","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T22:07:29Z","timestamp":1503353249000},"page":"159-167","source":"Crossref","is-referenced-by-count":67,"title":["Effects of Additive Tolvaptan vs. Increased Furosemide on Heart Failure With Diuretic Resistance and Renal Impairment\u3000\u2015 Results From the K-STAR Study \u2015"],"prefix":"10.1253","volume":"82","author":[{"given":"Takayuki","family":"Inomata","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University Kitasato Institute Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kida","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Shibagaki","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sato","sequence":"additional","affiliation":[{"name":"Internal Medicine and Cardiology, Nippon Medical School Musashi-Kosugi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kumagai","sequence":"additional","affiliation":[{"name":"Kitasato Academic Research Organization, Kitasato University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisahito","family":"Shinagawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Ako","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kitasato University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Izumi","sequence":"additional","affiliation":[{"name":"Niigata Minami Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Kanagawa Aquaresis Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: Findings from the EVEREST trial. <i>Eur Heart J<\/i> 2013; 34: 835\u2013843.","DOI":"10.1093\/eurheartj\/ehs444"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Ellison DH. Diuretic therapy and resistance in congestive heart failure. <i>Cardiology<\/i> 2001; 96: 132\u2013143.","DOI":"10.1159\/000047397"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L, Parikh CR, et al. Loop diuretic efficiency: A metric of diuretic responsiveness with prognostic importance in acute decompensated heart failure. <i>Circ Heart Fail<\/i> 2014; 7: 261\u2013270.","DOI":"10.1161\/CIRCHEARTFAILURE.113.000895"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Singh D, Shrestha K, Testani JM, Verbrugge FH, Dupont M, Mullens W, et al. Insufficient natriuretic response to continuous intravenous furosemide is associated with poor long-term outcomes in acute decompensated heart failure. <i>J Card Fail<\/i> 2014; 20: 392\u2013399.","DOI":"10.1016\/j.cardfail.2014.03.006"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Kr\u00e4mer BK, Schweda F, Kammerl M, Riegger GA. Diuretic therapy and diuretic resistance in cardiac failure. <i>Nephrol Dial Transplant<\/i> 1999; 14(Suppl 4): 39\u201342.","DOI":"10.1093\/ndt\/14.suppl_4.39"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. <i>N Engl J Med<\/i> 2011; 364: 797\u2013805.","DOI":"10.1056\/NEJMoa1005419"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V<sub>2<\/sub>-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. <i>J Pharmacol Exp Ther<\/i> 1998; 287: 860\u2013867.","DOI":"10.1016\/S0022-3565(24)37873-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. <i>JAMA<\/i> 2007; 297: 1332\u20131343.","DOI":"10.1001\/jama.297.12.1332"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Matsue Y, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, et al. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. <i>J Card Fail<\/i> 2016; 22: 423\u2013432.","DOI":"10.1016\/j.cardfail.2016.02.007"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Jujo K, Saito K, Ishida I, Furuki Y, Kim A, Suzuki Y, et al. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. <i>ESC Heart Fail<\/i> 2016; 3: 177\u2013188.","DOI":"10.1002\/ehf2.12088"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. <i>J Cardiol<\/i> 2016; 67: 399\u2013405.","DOI":"10.1016\/j.jjcc.2015.09.020"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Imamura T, Kinugawa K, Ohtani T, Sakata Y, Higo T, Kinugawa S, et al. Assessment of quality of life during long-term treatment of tolvaptan in refractory heart failure: Design and rationale of the AQUA-TLV Study. <i>Int Heart J<\/i> 2014; 55: 264\u2013267.","DOI":"10.1536\/ihj.13-326"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Inker LA, Astor BC, Fox CH, Isakova T, Lash JP, Peralta CA, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. <i>Am J Kidney Dis<\/i> 2014; 63: 713\u2013735.","DOI":"10.1053\/j.ajkd.2014.01.416"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kajimoto K, Sato N, Takano T; ATTEND investigators. eGFR and outcomes in patients with acute decompensated heart failure with or without elevated BUN. <i>Clin J Am Soc Nephrol<\/i> 2016; 11: 405\u2013412.","DOI":"10.2215\/CJN.08210815"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Suzuki S, Yoshihisa A, Yamaki T, Sugimoto K, Kunii H, Nakazato K, et al. Acute heart failure volume control multicenter randomized (AVCMA) trial: Comparison of tolvaptan and carperitide. <i>J Clin Pharmacol<\/i> 2013; 53: 1277\u20131285.","DOI":"10.1002\/jcph.197"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Matsue Y, Suzuki M, Nagahori W, Yoshida K, Onishi Y, Satoh Y, et al. Clinical effectiveness of tolvaptan in patients with acute decompensated heart failure and renal failure: Design and rationale of the AQUAMARINE study. <i>Cadiovasc Drugs Ther<\/i> 2014; 28: 73\u201377.","DOI":"10.1007\/s10557-013-6491-8"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Testani JM, McCauley BD, Chen J, Shumski M, Shannon RP. Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions. <i>Cardiology<\/i> 2010; 116: 206\u2013212.","DOI":"10.1159\/000316038"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. de Silva R, Nikitin NP, Witte KK, Rigby AS, Goode K, Bhandari S, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: Contributing factors and relationship to prognosis. <i>Eur Heart J<\/i> 2006; 27: 569\u2013581.","DOI":"10.1093\/eurheartj\/ehi696"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Matsuzaki M, Hori M, Izumi T, Fukunami M; Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A Phase III, randomized, double-blind, placebo-controlled Study (QUEST Study). <i>Cardiovasc Drugs Ther<\/i> 2011; 25(Suppl 1): S33\u2013S45.","DOI":"10.1007\/s10557-011-6304-x"},{"key":"20","unstructured":"20. Verbrugge FH, Dupont M, Steels P, Grieten L, Swennen Q, Tang WH, et al. The kidney in congestive heart failure: Are natriuresis, sodium, and diuretics really the good, the bad and the ugly? <i>Eur J Heart Fail<\/i> 2014; 16: 133\u2013142."},{"key":"21","unstructured":"21. Hoorn EJ, Wilcox CS, Ellison DH. Diuretics. <i>In<\/i>: Skorecki K, Chertow G, Marsden P, Taal M, Yu A, editors. Brenner and Rector\u2019s the kidney, Vol. 2, 10th edn. Philadelphia: Elsevier, 2015; 1702\u20131734."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Kinugawa K, Inomata T, Sato N, Yasuda M, Shimakawa T, Bando K, et al. Effectiveness and adverse events of tolvaptan in octogenarians with heart failure. Interim analyses of Samsca Post-Marketing Surveillance In Heart faiLurE (SMILE study). <i>Int Heart J<\/i> 2015; 56: 137\u2013143.","DOI":"10.1536\/ihj.14-332"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kinugawa K, Sato N, Inomata T, Shimakawa T, Iwatake N, Mizuguchi K. Efficacy and safety of tolvaptan in heart failure patients with volume overload. <i>Circ J<\/i> 2014; 78: 844\u2013852.","DOI":"10.1253\/circj.CJ-66-0093"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. <i>Eur Heart J<\/i> 2014; 35: 455\u2013469.","DOI":"10.1093\/eurheartj\/eht386"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chen HH, Anstrom KJ, Givertz MM, Stevenson LW, Semigran MJ, Goldsmith SR, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: The ROSE acute heart failure randomized trial. <i>JAMA<\/i> 2013; 310: 2533\u20132543.","DOI":"10.1001\/jama.2013.282190"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. O\u2019Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Effect of nesiritide in patients with acute decompensated heart failure. <i>N Engl J Med<\/i> 2011; 365: 32\u201343.","DOI":"10.1056\/NEJMoa1100171"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. O\u2019Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. <i>Lancet<\/i> 2013; 381: 29\u201339.","DOI":"10.1016\/S0140-6736(12)61855-8"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Verbrugge FH, Dupont M, Bertrand PB, Nijst P, Penders J, Dens J, et al. Determinants and impact of the natriuretic response to diuretic therapy in heart failure with reduced ejection fraction and volume overload. <i>Acta Cardiol<\/i> 2015; 70: 265\u2013273.","DOI":"10.1080\/AC.70.3.3080630"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. <i>J Cardiol<\/i> 2012; 60: 462\u2013469.","DOI":"10.1016\/j.jjcc.2012.09.002"},{"key":"30","unstructured":"30. Goldsmith SR, Bart BA, Burnett J. Decongestive therapy and renal function in acute heart failure: Time for a new approach? <i>Circ Heart Fail<\/i> 2014; 7: 531\u2013535."},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. <i>J Card Fail<\/i> 2010; 16: 541\u2013547.","DOI":"10.1016\/j.cardfail.2010.02.001"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. <i>Circulation<\/i> 2010; 122: 265\u2013272.","DOI":"10.1161\/CIRCULATIONAHA.109.933275"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/1\/82_CJ-17-0179\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:11:49Z","timestamp":1750810309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/82\/1\/82_CJ-17-0179\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-17-0179","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}